E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Multiple myeloma |
Múltiple mieloma |
|
E.1.1.1 | Medical condition in easily understood language |
Multiple myeloma Daratumumab Early access |
Multiple mieloma Daratumumab Acceso temprano |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028228 |
E.1.2 | Term | Multiple myeloma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available for subjects with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD. |
El objetivo de este estudio es proporcionar acceso anticipado al tratamiento con daratumumab y recopilar datos de seguridad adicionales mientras el medicamento no esté comercializado para los pacientes con mieloma múltiple que han recibido al menos 3 líneas de tratamiento previas, incluido un inhibidor del proteasoma (IP) y un fármaco inmunomodulador (FIM), o que tienen resistencia doble, tanto a un inhibidor del IP como a un FIM. |
|
E.2.2 | Secondary objectives of the trial |
There is no hypothesis associated with this objective. |
No hay hipótesis asociada con este objetivo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Subject must be at least 18 years of age - Subject must have documented multiple myeloma and have evidence of disease progression on or after the most recent prior treatment regimen as defined by IMWG criteria: Subjects who have received at least 3 prior lines of therapy including a proteasome inhibitor (greater than or equal to [>=] 2 cycles or 2 months of treatment) and an IMiD (>= 2 cycles or 2 months of treatment) in any order during the course of treatment (except for subjects who discontinued either of these treatments due to a severe allergic reaction within the first 2 cycles/months) OR Subjects whose disease is double refractory to a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD). For subjects who have received more than 1 type of PI, their disease must be refractory to the most recent one. Similarly, for those who have received more than 1 type of IMiD, their disease must be refractory to the most recent one - Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1,or 2 - A woman of childbearing potential must have a negative serum or urine pregnancy test at Screening - A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control during the study, and all men must also not donate sperm during the study and for 6 months after receiving the last dose of study drug |
- Sujeto ? 18 años de edad -El sujeto debe tener documentado Mieloma Multiple y tener evidencia de progresión de la enfermedad al tratamiento anterior más reciente definido por los criterios internacionales IMWG Sujetos que hayan recibido al menos 3 líneas previas de tratamiento incluyendo un inhibidor del proteasoma (mayor o igual a 2 ciclos o 2 meses de tratamiento) y un agente inmunomudolador ( 2 ciclos o 2 meses de tratamiento) en cualquier orden durante el curso del tratamiento (excepto en sujetos que discontinuan cualquiera de los tratamientos debido a reacción alergica severa dentro de los dos primeros ciclos/meses) o sujetos cuya enfermedad es doble refractaria a un inhibidor del proteasoma (IP) y un agente inmunomodulador (IMiD). Para sujetos que hayan recibido más de un tipo de IP, su enfermedad debe ser refractaria al más reciente. Similarmente, para aquellos que hayan recibido más de un tipo de IMiD, su enfermedad debe ser refractaria al más reciente. - Sujetos con estado funcional (ECOG) 0, 1 ó 2. - Prueba de embarazo negativa en orina o suero en la visita de selección en mujer fértil. - Hombre sexualmente activo con una mujer en edad fértil y no vasectomizado deben acordar usar un método anticonceptivo de barrera durante el estudio, así como también todos los hombres no deben donar esperma durante el estudio y durante 6 meses después de recibir la última dosis del fármaco. |
|
E.4 | Principal exclusion criteria |
- Ever enrolled in another daratumumab study or eligible for enrollment in another ongoing clinical study of daratumumab - Subject receives any other anti-myeloma therapy while receiving daratumumab - Enrolled in another interventional clinical study with therapeutic intent - Subject has known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) less than 50% of predicted normal - Subject has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification - Prior exposure to any anti-CD38 monoclonal antibody |
- Haber estado incluido en otro studio de Daratumumbar o elegible para ser incluido en otro estudio clínico en marcha con Daratumumab. - Sujeto que reciba otra terapia anti mieloma mientras reciban daratumumab. - Incluido en otro estudio clínico intervencional con intención terapeutica. - Sujeto con conocimiento de Enfermedad obstructiva pulmonar crónica (EPOC) con un volumen espiratorio forzado en 1 segundo (FEV1) inferior al 50% del valor de lo normal - Sujeto con conocimiento de asma persistente moderada o grave en los últimos 2 años, o que actualmente ha no controlada el asma de cualquier clasificación - Exposición previa a cualquier anticuerpo monoclonal anti-CD38 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 58 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Italy |
Russian Federation |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Each country will be closed to enrollment when HA appr. has been received or the max. nr. of subjects have been enrolled.Enrolled subjects will be transitioned from study drug to commercial product once commercial product is available by doctor?s prescription or when daratumumab can be accessed from another source,and will be withdrawn from this study at that time.Study will be completed when the last study assessment for the last subject is complete.Further information within the study protocol |
La inclusión en cada país se cerrará cuando se reciba la aprobación de las autoridades o se haya incluido al número máximo de sujetos. Los sujetos pasarán del fármaco del estudio al producto comercial cuando éste se encuentre disponible con receta o cuando se pueda acceder a él por otra vía, y serán retirados de este estudio en ese momento. El estudio se considerará finalizado con la última evaluación del estudio del último sujeto participante en el mismo. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |